Debrief: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Pents-Refractory Multiple Myeloma
Karyopharm, a clinical-stage pharmaceutical company of Newton Mass recently announced amazing success on a project supported by Court Square: “Phase 2b STORM (Selinexor Treatment of Refractory Myeloma) study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma.”
(Multiple Myeloma is a specified cancer of plasma cells. Plasma cells are a type of white blood cell that exists within the body known to fight disease. When multiple myeloma occurs within the body, the white blood cells that create the plasma of our bone marrow group together and begin to cause painful damage to the bones, the immune system, kidneys, and red blood cell count.)
In this study, the drug was administered to patients who had a highly resistant form of the disease (“refractory multiple”) and had been unresponsive to alternative treatments. The data collected from Karyopharms study of the new drug selinaxor shows a 25.4% overall response rate. Because of this positive response to the drug, the FDA has now added selinaxor to the “Fast-track”—Karyopharm plans to submit a New Drug application to the FDA by the conclusion of 2018.
Karyopharm Therapeutics Inc. has focused on achieving commercialization for selinaxor, and approvals to move the drug into accessible therapies for cancer patients. “Our goal is to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first in class small molecule modulators of nuclear transport into effective chronic therapeutics for life-threatening conditions.”
Congratulations go out to Karyopharm for achieving this meaningful goal and milestone!
Court Square is proud to witness and be a part of your success.
To review the full press release, click here.